Answers are grounded in this paper and cite their sources.
Despite traditional molecular research advances being translated into approved targeted agents, including cetuximab, panitumumab and bevacizumab, the overall survival benefit of patients with color...
No takes yet. Share an insight, caveat, or question.
Roukos et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: